clonidine has been researched along with Panic Disorder in 26 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
Panic Disorder: A type of anxiety disorder characterized by unexpected panic attacks that last minutes or, rarely, hours. Panic attacks begin with intense apprehension, fear or terror and, often, a feeling of impending doom. Symptoms experienced during a panic attack include dyspnea or sensations of being smothered; dizziness, loss of balance or faintness; choking sensations; palpitations or accelerated heart rate; shakiness; sweating; nausea or other form of abdominal distress; depersonalization or derealization; paresthesias; hot flashes or chills; chest discomfort or pain; fear of dying and fear of not being in control of oneself or going crazy. Agoraphobia may also develop. Similar to other anxiety disorders, it may be inherited as an autosomal dominant trait.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Growth-hormone (GH) responses to the alpha 2-adrenoceptor agonist clonidine were measured in 9 panic disorder patients, in 9 patients fulfilling DSM-III-R criteria for major depressive episode, and in 9 age- and sex-matched controls." | 9.08 | Growth-hormone response to clonidine in panic disorder patients in comparison to patients with major depression and healthy controls. ( Berger, M; Gann, H; Müller, WE; Riemann, D; Stoll, S, 1995) |
| ") and to clonidine (150 micrograms) were measured in 10 outpatients with panic disorder before and after 30 days of 2-2." | 9.08 | Alpha 2-adrenergic receptor sensitivity in panic disorder: I. GH response to GHRH and clonidine stimulation in panic disorder. ( Bellodi, L; Brambilla, F; Garberi, A; Nobile, P; Perna, G, 1995) |
| "The cortisol responses to acute administration of saline and of clonidine (Clon), 150 micrograms IV, were examined in 12 patients with panic disorder and agoraphobia, before and after 32 days of alprazolam therapy (2." | 9.08 | Alpha 2-adrenergic receptor sensitivity in panic disorder: II. Cortisol response to clonidine stimulation in panic disorder. ( Arancio, C; Bellodi, L; Brambilla, F; Nobile, P; Perna, G, 1995) |
| "The growth hormone (GH) response to intravenous administration of clonidine hydrochloride (2 micrograms/kg) was assessed in 16 patients with DSM-III-R social phobia, 13 patients with DSM-III-R panic disorder, and 31 healthy controls." | 9.07 | Growth hormone response to intravenous clonidine in social phobia: comparison to patients with panic disorder and healthy volunteers. ( Stein, MB; Tancer, ME; Uhde, TW, 1993) |
| "Blunted growth hormone (GH) responses to growth hormone-releasing factor (GH-RF) and clonidine have been reported in patients with panic disorder." | 9.07 | Blunted growth hormone responses to growth hormone-releasing factor and to clonidine in panic disorder. ( Black, B; Stein, MB; Tancer, ME; Uhde, TW, 1993) |
| "In order to evaluate possible abnormal noradrenergic neuronal functional regulation in patients with panic disorder, the behavioral, biochemical and cardiovascular effects of intravenous yohimbine (0." | 9.07 | Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients. ( Charney, DS; Heninger, GR; Krystal, JH; Nagy, LM; Woods, SW, 1992) |
| "We examined adrenergic regulation in patients with panic disorder by challenging 10 patients and 14 age-matched and sex-matched controls with intravenous infusions of clonidine hydrochloride (2 micrograms/kg), an alpha 2-adrenoreceptor agonist." | 9.07 | Endocrine, cardiovascular, and behavioral responses to clonidine in patients with panic disorder. ( Abelson, JL; Bronzo, M; Cameron, OG; Curtis, GC; Glitz, D; Lee, MA, 1992) |
| " Previously we demonstrated that panic disorder patients have blunted growth hormone (GH) responses to clonidine, an alpha 2-adrenergic agonist." | 8.78 | Evidence for hypothalamo-growth hormone dysfunction in panic disorder: profile of growth hormone (GH) responses to clonidine, yohimbine, caffeine, glucose, GRF and TRH in panic disorder patients versus healthy volunteers. ( Black, B; Boulenger, JP; Geraci, M; Gurguis, G; Post, RM; Roscow, DB; Rubinow, DR; Tancer, ME; Uhde, TW; Vittone, B, 1992) |
| "Seventeen patients with panic disorder and 15 healthy volunteers were challenged with clonidine." | 7.69 | Persistence of blunted human growth hormone response to clonidine in fluoxetine-treated patients with panic disorder. ( Cooper, T; Coplan, JD; Gorman, JM; Liebowitz, MR; Martinez, J; Papp, LA; Pine, D; Rosenblum, LA, 1995) |
| "We report a non-significantly higher growth hormone (GH) response to intravenous clonidine administration (150 micrograms) in 10 male patients with panic disorder who had never received antidepressant therapy than in 10 matched controls." | 7.68 | Growth hormone response to clonidine in male patients with panic disorder untreated by antidepressants. ( Ansseau, M; Charles, G; Machowski, R; Papart, P; Pichot, W; Schittecatte, M; Wilmotte, J, 1992) |
| "To assess the role of noradrenergic stimulation during lactate-induced panic, ten patients with panic disorder who panicked during a standard sodium-lactate infusion underwent a repeat infusion following intravenous clonidine pretreatment." | 7.68 | Noradrenergic function in panic disorder. Effects of intravenous clonidine pretreatment on lactate induced panic. ( Campeas, RB; Coplan, JD; Davies, SO; Dillon, DJ; Fyer, AJ; Gorman, JM; Klein, DF; Liebowitz, MR; Martinez, J, 1992) |
| " Several studies have shown that panic disorder is associated with an increased sensitivity to yohimbine and a blunted growth hormone response to clonidine, which are alpha-2 adrenoceptor antagonist and agonist, respectively." | 5.10 | Heart rate and QT interval variability: abnormal alpha-2 adrenergic function in patients with panic disorder. ( Tancer, M; Uhde, T; Yeragani, VK, 2003) |
| "Growth-hormone (GH) responses to the alpha 2-adrenoceptor agonist clonidine were measured in 9 panic disorder patients, in 9 patients fulfilling DSM-III-R criteria for major depressive episode, and in 9 age- and sex-matched controls." | 5.08 | Growth-hormone response to clonidine in panic disorder patients in comparison to patients with major depression and healthy controls. ( Berger, M; Gann, H; Müller, WE; Riemann, D; Stoll, S, 1995) |
| ") and to clonidine (150 micrograms) were measured in 10 outpatients with panic disorder before and after 30 days of 2-2." | 5.08 | Alpha 2-adrenergic receptor sensitivity in panic disorder: I. GH response to GHRH and clonidine stimulation in panic disorder. ( Bellodi, L; Brambilla, F; Garberi, A; Nobile, P; Perna, G, 1995) |
| "The cortisol responses to acute administration of saline and of clonidine (Clon), 150 micrograms IV, were examined in 12 patients with panic disorder and agoraphobia, before and after 32 days of alprazolam therapy (2." | 5.08 | Alpha 2-adrenergic receptor sensitivity in panic disorder: II. Cortisol response to clonidine stimulation in panic disorder. ( Arancio, C; Bellodi, L; Brambilla, F; Nobile, P; Perna, G, 1995) |
| "The growth hormone (GH) response to intravenous administration of clonidine hydrochloride (2 micrograms/kg) was assessed in 16 patients with DSM-III-R social phobia, 13 patients with DSM-III-R panic disorder, and 31 healthy controls." | 5.07 | Growth hormone response to intravenous clonidine in social phobia: comparison to patients with panic disorder and healthy volunteers. ( Stein, MB; Tancer, ME; Uhde, TW, 1993) |
| "Blunted growth hormone (GH) responses to growth hormone-releasing factor (GH-RF) and clonidine have been reported in patients with panic disorder." | 5.07 | Blunted growth hormone responses to growth hormone-releasing factor and to clonidine in panic disorder. ( Black, B; Stein, MB; Tancer, ME; Uhde, TW, 1993) |
| "In order to evaluate possible abnormal noradrenergic neuronal functional regulation in patients with panic disorder, the behavioral, biochemical and cardiovascular effects of intravenous yohimbine (0." | 5.07 | Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients. ( Charney, DS; Heninger, GR; Krystal, JH; Nagy, LM; Woods, SW, 1992) |
| "We examined adrenergic regulation in patients with panic disorder by challenging 10 patients and 14 age-matched and sex-matched controls with intravenous infusions of clonidine hydrochloride (2 micrograms/kg), an alpha 2-adrenoreceptor agonist." | 5.07 | Endocrine, cardiovascular, and behavioral responses to clonidine in patients with panic disorder. ( Abelson, JL; Bronzo, M; Cameron, OG; Curtis, GC; Glitz, D; Lee, MA, 1992) |
| " Previously we demonstrated that panic disorder patients have blunted growth hormone (GH) responses to clonidine, an alpha 2-adrenergic agonist." | 4.78 | Evidence for hypothalamo-growth hormone dysfunction in panic disorder: profile of growth hormone (GH) responses to clonidine, yohimbine, caffeine, glucose, GRF and TRH in panic disorder patients versus healthy volunteers. ( Black, B; Boulenger, JP; Geraci, M; Gurguis, G; Post, RM; Roscow, DB; Rubinow, DR; Tancer, ME; Uhde, TW; Vittone, B, 1992) |
| " We therefore conducted this pilot study to compare a group of patients with post-traumatic stress disorder (PTSD) (n = 7) to a contiguously studied panic disorder group (n = 17) and healthy control subjects (n = 16) on baseline levels of cortisol and 3-methoxy-4-hydroxyphenylglycol (MHPG), and response to clonidine challenge." | 3.71 | A pilot study of noradrenergic and HPA axis functioning in PTSD vs. panic disorder. ( Blanco, C; Coplan, J; Klein, DF; Liebowitz, MR; Marshall, RD; Printz, D, 2002) |
| "Seventeen patients with panic disorder and 15 healthy volunteers were challenged with clonidine." | 3.69 | Persistence of blunted human growth hormone response to clonidine in fluoxetine-treated patients with panic disorder. ( Cooper, T; Coplan, JD; Gorman, JM; Liebowitz, MR; Martinez, J; Papp, LA; Pine, D; Rosenblum, LA, 1995) |
| "Phenelzine (PLZ), a nonselective monoamine oxidase inhibitor, is widely used in psychiatry for the treatment of panic disorder and depression." | 3.68 | Chronic administration of the antidepressant-antipanic drug phenelzine and its N-acetylated analogue: effects on monoamine oxidase, biogenic amines, and alpha 2-adrenoreceptor function. ( Baker, GB; Coutts, RT; Greenshaw, AJ; McKenna, KF, 1992) |
| "We report a non-significantly higher growth hormone (GH) response to intravenous clonidine administration (150 micrograms) in 10 male patients with panic disorder who had never received antidepressant therapy than in 10 matched controls." | 3.68 | Growth hormone response to clonidine in male patients with panic disorder untreated by antidepressants. ( Ansseau, M; Charles, G; Machowski, R; Papart, P; Pichot, W; Schittecatte, M; Wilmotte, J, 1992) |
| "To assess the role of noradrenergic stimulation during lactate-induced panic, ten patients with panic disorder who panicked during a standard sodium-lactate infusion underwent a repeat infusion following intravenous clonidine pretreatment." | 3.68 | Noradrenergic function in panic disorder. Effects of intravenous clonidine pretreatment on lactate induced panic. ( Campeas, RB; Coplan, JD; Davies, SO; Dillon, DJ; Fyer, AJ; Gorman, JM; Klein, DF; Liebowitz, MR; Martinez, J, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 21 (80.77) | 18.2507 |
| 2000's | 4 (15.38) | 29.6817 |
| 2010's | 1 (3.85) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Garcha, AS | 1 |
| Cohen, DL | 1 |
| Marshall, RD | 1 |
| Blanco, C | 1 |
| Printz, D | 1 |
| Liebowitz, MR | 3 |
| Klein, DF | 3 |
| Coplan, J | 1 |
| Yeragani, VK | 1 |
| Tancer, M | 1 |
| Uhde, T | 1 |
| Valenca, AM | 2 |
| Mezzasalma, MA | 2 |
| Nascimento, I | 2 |
| Lopes, FL | 2 |
| Zin, WA | 2 |
| Nardi, AE | 2 |
| Versiani, M | 1 |
| Gann, H | 1 |
| Riemann, D | 1 |
| Stoll, S | 1 |
| Berger, M | 1 |
| Müller, WE | 1 |
| Coplan, JD | 6 |
| Papp, LA | 3 |
| Martinez, J | 4 |
| Pine, D | 3 |
| Rosenblum, LA | 3 |
| Cooper, T | 3 |
| Gorman, JM | 6 |
| Brambilla, F | 2 |
| Perna, G | 2 |
| Garberi, A | 1 |
| Nobile, P | 2 |
| Bellodi, L | 2 |
| Arancio, C | 1 |
| Roy-Byrne, PP | 1 |
| Sullivan, MD | 1 |
| Cowley, DS | 1 |
| Ries, RK | 1 |
| Puzantian, T | 1 |
| Hart, LL | 1 |
| Tancer, ME | 3 |
| Stein, MB | 2 |
| Uhde, TW | 3 |
| Black, B | 2 |
| Papp, L | 1 |
| Pine, DS | 1 |
| Kellner, M | 2 |
| Wiedemann, K | 2 |
| Yassouridis, A | 1 |
| Jahn, H | 1 |
| Hug, B | 1 |
| Charney, DS | 1 |
| Woods, SW | 1 |
| Krystal, JH | 1 |
| Nagy, LM | 1 |
| Heninger, GR | 1 |
| McKenna, KF | 1 |
| Baker, GB | 1 |
| Coutts, RT | 1 |
| Greenshaw, AJ | 1 |
| Abelson, JL | 1 |
| Glitz, D | 1 |
| Cameron, OG | 1 |
| Lee, MA | 1 |
| Bronzo, M | 1 |
| Curtis, GC | 1 |
| Schittecatte, M | 1 |
| Ansseau, M | 1 |
| Charles, G | 1 |
| Machowski, R | 1 |
| Papart, P | 1 |
| Pichot, W | 1 |
| Wilmotte, J | 1 |
| Rubinow, DR | 1 |
| Roscow, DB | 1 |
| Boulenger, JP | 1 |
| Vittone, B | 1 |
| Gurguis, G | 1 |
| Geraci, M | 1 |
| Post, RM | 1 |
| Fyer, AJ | 1 |
| Dillon, DJ | 1 |
| Campeas, RB | 1 |
| Davies, SO | 1 |
6 reviews available for clonidine and Panic Disorder
| Article | Year |
|---|---|
Catecholamine excess: pseudopheochromocytoma and beyond.
Topics: Adrenal Gland Neoplasms; Adrenergic Agents; Antihypertensive Agents; Autonomic Nervous System Diseas | 2015 |
Adjunctive treatment of benzodiazepine discontinuation syndromes: a review.
Topics: Anti-Anxiety Agents; Benzodiazepines; Carbamazepine; Clonidine; Combined Modality Therapy; Humans; P | 1993 |
Clonidine in panic disorder.
Topics: Clinical Trials as Topic; Clonidine; Humans; Infusions, Intravenous; Panic Disorder | 1993 |
Comorbidity of depression and panic disorder.
Topics: Adult; Clonidine; Comorbidity; Depressive Disorder; Human Growth Hormone; Humans; Panic Disorder; Pr | 1996 |
A view on noradrenergic, hypothalamic-pituitary-adrenal axis and extrahypothalamic corticotrophin-releasing factor function in anxiety and affective disorders: the reduced growth hormone response to clonidine.
Topics: Animals; Anxiety; Clonidine; Corticotropin-Releasing Hormone; Depressive Disorder; Growth Hormone; H | 1997 |
Evidence for hypothalamo-growth hormone dysfunction in panic disorder: profile of growth hormone (GH) responses to clonidine, yohimbine, caffeine, glucose, GRF and TRH in panic disorder patients versus healthy volunteers.
Topics: Caffeine; Clonidine; Glucose; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Hypothalamus | 1992 |
9 trials available for clonidine and Panic Disorder
| Article | Year |
|---|---|
Heart rate and QT interval variability: abnormal alpha-2 adrenergic function in patients with panic disorder.
Topics: Adrenergic alpha-Agonists; Adult; Clonidine; Double-Blind Method; Female; Heart Rate; Humans; Long Q | 2003 |
Growth-hormone response to clonidine in panic disorder patients in comparison to patients with major depression and healthy controls.
Topics: Adrenergic alpha-Agonists; Adult; Clonidine; Depressive Disorder; Female; Growth Hormone; Humans; Ma | 1995 |
Alpha 2-adrenergic receptor sensitivity in panic disorder: I. GH response to GHRH and clonidine stimulation in panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Clonidine; Female; Growth Hormone; Growth Hormone-Releasing Hormone; | 1995 |
Alpha 2-adrenergic receptor sensitivity in panic disorder: II. Cortisol response to clonidine stimulation in panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Clonidine; Female; Humans; Hydrocortisone; Male; Middle Aged; Panic | 1995 |
Growth hormone response to intravenous clonidine in social phobia: comparison to patients with panic disorder and healthy volunteers.
Topics: Adult; Clonidine; Diagnosis, Differential; Double-Blind Method; Female; Growth Hormone; Humans; Infu | 1993 |
Blunted growth hormone responses to growth hormone-releasing factor and to clonidine in panic disorder.
Topics: Adult; Analysis of Variance; Clonidine; Diagnosis, Differential; Double-Blind Method; Female; Growth | 1993 |
Influence of clonidine on psychopathological, endocrine and respiratory effects of cholecystokinin tetrapeptide in patients with panic disorder.
Topics: Adrenergic alpha-Agonists; Adrenocorticotropic Hormone; Adult; Clonidine; Double-Blind Method; Femal | 1997 |
Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients.
Topics: Adult; Arousal; Blood Pressure; Clonidine; Double-Blind Method; Female; Growth Hormone; Humans; Hydr | 1992 |
Endocrine, cardiovascular, and behavioral responses to clonidine in patients with panic disorder.
Topics: Adrenergic Fibers; Adult; Arousal; Blood Pressure; Clonidine; Female; Growth Hormone; Heart Rate; Hu | 1992 |
11 other studies available for clonidine and Panic Disorder
| Article | Year |
|---|---|
A pilot study of noradrenergic and HPA axis functioning in PTSD vs. panic disorder.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Aged; Clonidine; Eye Movements; Female; Gas Chromatogr | 2002 |
Respiratory panic disorder treatment with clonidine.
Topics: Adult; Clonidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyspnea; Female; H | 2004 |
Clonidine in respiratory panic disorder subtype.
Topics: Adrenergic alpha-Agonists; Adult; Clonidine; Female; Humans; Panic Disorder; Respiration Disorders | 2004 |
Persistence of blunted human growth hormone response to clonidine in fluoxetine-treated patients with panic disorder.
Topics: Clonidine; Female; Fluoxetine; Growth Hormone; Humans; Male; Panic Disorder; Psychiatric Status Rati | 1995 |
Uncoupling of the noradrenergic-hypothalamic-pituitary-adrenal axis in panic disorder patients.
Topics: Adrenal Cortex; Adult; Clonidine; Female; Fluoxetine; Humans; Hypothalamo-Hypophyseal System; Male; | 1995 |
Clinical improvement with fluoxetine therapy and noradrenergic function in patients with panic disorder.
Topics: Adult; Clonidine; Female; Fluoxetine; Humans; Hydrocortisone; Male; Methoxyhydroxyphenylglycol; Nore | 1997 |
Atrial natriuretic hormone responses to clonidine in patients with panic disorder and in healthy control subjects.
Topics: Adrenergic alpha-Agonists; Adult; Atrial Natriuretic Factor; Clonidine; Female; Humans; Male; Panic | 1997 |
[Panic disorder].
Topics: Adrenal Gland Neoplasms; Aged; Clonidine; Diagnosis, Differential; Epinephrine; Female; Humans; Nore | 1998 |
Chronic administration of the antidepressant-antipanic drug phenelzine and its N-acetylated analogue: effects on monoamine oxidase, biogenic amines, and alpha 2-adrenoreceptor function.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antidepressive Agents; Biogenic Amines; Body Weight; Brain; | 1992 |
Growth hormone response to clonidine in male patients with panic disorder untreated by antidepressants.
Topics: Adult; Clonidine; Growth Hormone-Releasing Hormone; Humans; Injections, Intravenous; Male; Middle Ag | 1992 |
Noradrenergic function in panic disorder. Effects of intravenous clonidine pretreatment on lactate induced panic.
Topics: Adult; Blood Pressure; Clonidine; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intra | 1992 |